InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for
two weeks on immune reconstitution of lymphopenic COVID-19 patients.
Phase:
Phase 2
Details
Lead Sponsor:
Revimmune
Collaborators:
Amarex Clinical Research University Hospital, Limoges